M. Hizal (Ankara, Turkey)
Ankara City HospitalAuthor Of 1 Presentation
- M. Sendur (Ankara, Turkey)
- B. Cakar (Izmir, Turkey)
- M. Hizal (Ankara, Turkey)
- E. Eraslan (Ankara, Turkey)
- S. Aksoy (Ankara, Turkey)
- S. Paydas (Adana, Turkey)
- N. Demir (Sivas, Turkey)
- F. Sen (Istanbul, Turkey)
- G. Bulut (Hatay, Turkey)
- K. Oruc (Istanbul, Turkey)
- B. Oyan Uluc (Istanbul, Turkey)
- N. Ozdemir (Ankara, Turkey)
- A. Sakin (Van, Turkey)
- D. Erdem (Istanbul, Turkey)
- M. Özkan (Kayseri, Turkey)
- U. Disel (Adana, Turkey)
- F. Ekinci (Manisa, Turkey)
- I. Ökten (Istanbul, Turkey)
- L. Ozer (Istanbul, Turkey)
- E. Gokmen (Izmir, Turkey)
124P - Talazoparib in Local Advanced or Metastatic Breast Cancer Patients: Experience from an Early Access Program in Turkey
Abstract
Background
Talazoparib is a potent PARP inhibitor and has shown progression-free survival (PFS) advantage in phase III EMBRACA study which randomized BRCA-mutant breast cancer patients In this study, we aimed to determine the real-life efficacy and safety profile of Talazoparib in BRCA-mutant breast cancer patients in Turkey.
Methods
In this study, advanced breast cancer patients with BRCA1 or BRCA2 mutation who received Talazoparib treatment via early access program were retrospectively analyzed. The data of the patients collected from 24 different oncology centers in Turkey.
Results
There were 47 advanced breast cancer patients (46 female and one male). The median age was 41.5. The percentages of the disease-subtype were 63.8% for hormone-positive disease and 36.2% for triple-negative (TNBC) disease. 76.6% of the patients had visceral and 12.8% of the patients had CNS metastasis. Previous exposure to platinum compounds was 53.2%. 48.9% of the patients (n=23) received the drug as first, second, or third-line. The rest of the patients (n=24, 51.1%) received Talazoparib treatment after third-line treatment. The objective response rate (ORR) was 31.9% (n=15) and disease-control rate was 61.7% (n=29). In 10.6% of patients complete response was achieved with Talazoparib treatment. After median 13.6 months (min-max. 6.5 - 21.5) follow-up, the median PFS (29 event) for Talazoparib treatment was 6.5 months (5.0 - 8.1 months, 95% CI). The median PFS for the patient subgroup who received the treatment in the first, second, or third-line was 9.9 months (4.4 – 15.5 months, 95% CI). The median PFS was 12.6 and 5.1 months for BRCA1 (n=18) and BRCA2 (n=21) patients, respectively. There were no PFS differences between subgroups according to hormone-receptor status or TNBC. The median OS for Talazoparib treatment had not been reached but the estimated 12-month OS rate was 73.6%.At least one side effect reported in 61.7% of the patients and grade 3-4 toxicity was seen in 14 patients (29.8%). The most common side effect was hematologic cytotoxicity.
Conclusions
Our study demonstrated favorable PFS and ORR results in a heavily-pretreated real-life BRCA-mutant advanced breast cancer cohort.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.